(Information sent by the signatory company)

-Dr. Joseph E. Eid, who led the pioneering clinical development of KEYTRUDA® at Merck, joins Dragonfly Therapeutics as President of R&D

Dr. Eid joins Dragonfly after 20 years of clinical development experience at Roche, Merck, and BMS, including serving as team leader at Merck on the first-in-human trial of pembrolizumab (anti-PD-1 antibody) he led to the KEYTRUDA® registry. He will be responsible for all aspects of clinical development and research at the company.

WALTHAM, Mass., Feb. 1, 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced that Dr. Joseph E. Eid has joined the company as President of Research and Development. Dr. Eid brings 20 years of in-depth experience in the clinical development of immunotherapies, including his work as team leader at Merck on the first-in-human trial with pembrolizumab (anti-PD-1 antibody) that led to the registration of KEYTRUDA ┬«. He will be responsible for all aspects of clinical development and research at Dragonfly.

“We are delighted to welcome Joe to Dragonfly,” said Bill Haney, Co-Founder and CEO of Dragonfly. “Joe’s world-class experience in immunotherapeutic drug development will be critical as we rapidly move into the clinic with our three proprietary immunotherapy candidates, including our Phase 2 HER2-targeted and Phase 1 EGFR-targeted TriNKETsTM , and our novel investigational immunotherapy with the cytokine interleukin-12 (IL-12), currently in dose escalation Phase 1. Joe’s track record of building clinical teams and creatively and effectively accelerating early clinical trials of its kind is impressive, and it joins Dragonfly in a transformative moment for us.” “

“I am excited to join Dragonfly as its novel NK cell and cytokine immunotherapies reach therapeutic dose levels in patients,” said Dr. Eid. “At Merck I helped initiate the clinical development of pembrolizumab, which is a game changer for cancer patients. At Dragonfly I will be passionate about bringing the company’s rich portfolio of next-generation immunomotors to patients with cancer and other diseases debilitating conditions in desperate need of new treatments.”

Dr. Joseph E. Eid is a physician specializing in medical oncology, hematology, and internal medicine. In his 20-year career in clinical development, Joe has contributed to several leading therapies from early clinical phases to his approval. In addition to his years at Merck, Joe was also Senior Vice President and Head of Global Medical Affairs at BMS, as well as Clinical Oncology Research Leader at Roche Pharmacuticals.

Joe received his medical degree from the St. Joseph University School of Medicine in Beirut, Lebanon. He completed his fellowship in hematology and medical oncology at Rutgers-Robert Wood Johnson Medical School (RWJMS) and subsequently served as Assistant Professor of Medicine and Pathology in the Departments of Medicine and Pathology and Laboratory Medicine and held a clinic for over 20 years.

About Dragonfly Dragonfly Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapies that use its novel bispecific antibody technology to harness the body’s immune system and deliver innovative treatments to patients. In addition to its proprietary clinical assets, Dragonfly has a broad portfolio of proprietary preclinical candidates discovered through its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead, and Bristol Myers Squibb in a wide range of pathology areas.

For more information, visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx

DRAGONFLY MEDIA CONTACT: Anne Deconinck | anne.deconinck@dragonflytx.com

Logo – http://photos.prnewswire.com/prnh/201607…

View original content: https://www.prnewswire.com/news-releases/el-dr-joseph-e-eid-se-une-a-dragonfly-therapeutics-como-presidente-de-id-301736458.html